{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-004211","form_type":"8-K","ticker":"FLNA","cik":"0001069530","company_name":"FILANA THERAPEUTICS, INC.","filed_at":"2025-06-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.407238+00:00","generated_at":"2026-05-18T11:53:36.652692+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Cassava Sciences simufilam reduces seizures 60% in TSC mouse model; H1 2026 clinical trials planned","bullets":["Preclinical data: simufilam reduced seizure frequency by 60% vs. vehicle in focal onset seizure mouse model (p<0.0001).","More mice achieved seizure freedom: 11/32 simufilam vs. 3/29 vehicle (p=0.0343).","Human safety data from 1,929-patient Phase 3 Alzheimer's studies show favorable safety profile with no serious SAEs attributed to drug.","Company plans to initiate first clinical study in TSC-related epilepsy in H1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-004211","json":"https://secwatch.observer/filing/0001171843-25-004211.json","markdown":"https://secwatch.observer/filing/0001171843-25-004211.md","text":"https://secwatch.observer/filing/0001171843-25-004211.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1069530/000117184325004211/0001171843-25-004211-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1069530/000117184325004211/f8k_062925.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-18T11:53:36.652692+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}